MDX060-05E: An open-label, phase II, extension study of MDX-060 [iratumumab] with gemcitabine in patients with relapsed or refractory Hodgkin's disease previously treated in protocol MDX060-05

Trial Profile

MDX060-05E: An open-label, phase II, extension study of MDX-060 [iratumumab] with gemcitabine in patients with relapsed or refractory Hodgkin's disease previously treated in protocol MDX060-05

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2009

At a glance

  • Drugs Iratumumab (Primary) ; Gemcitabine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Nov 2009 Actual initiation date (1 Mar 2007) and primary outcome added as reported by M.D. Anderson Cancer Center record.
    • 23 Nov 2009 Status changed from not stated to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
    • 23 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2006-0122).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top